The clinical application of oral entecavir for antiviral therapy in patients with hepatitis B virus infection, and thus the pursuit of conversion, is often the result of the following two situations: i. 65%-90%: Conversion of hepatitis B virus DNA, also known as a functional cure, which means that the hepatitis B virus DNA is converted from the original high load to below the detection value, the probability of DNA conversion is very high, and can reach about 90% for major triplets and The probability of DNA reversion is very high, about 90% for major triplets and about 65% for minor triplets. Although the clinical cure of hepatitis B surface antigen is almost inaccessible, the transfer of hepatitis B virus DNA will greatly reduce the probability of cirrhosis and liver cancer in hepatitis B virus-infected patients, which is the main goal of the clinical application of entecavir antiviral therapy. This is the main goal of entecavir antiviral therapy. It is important to note that the use of entecavir antiviral therapy should not be discontinued without authorization, and discontinuation of the drug should be done under the guidance of a specialist, otherwise it will lead to the recurrence of the virus, and a few people will lose their lives due to heavy hepatitis.